Search

Displaying results 3991 - 4000 of 7456 in total
  1. Drug

    R1204

    go.drugbank.com/drugs/DB05118
    Experimental

    It is developed for the treatment of depression.

  2. Drug

    MDX-1379

    go.drugbank.com/drugs/DB05329
    Investigational

    MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.

  3. Drug

    Brivanib

    go.drugbank.com/drugs/DB11958
    Investigational

    Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. … Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).

  4. Drug

    TRO40303

    go.drugbank.com/drugs/DB16031
    Investigational

    TRO40303 is under investigation in clinical trial NCT01374321 (Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute

  5. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    The results showed potent inhibition of the target, suggesting that GC-373 holds therapeutic potential for Covid-19[A219036].

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Amelubant

    go.drugbank.com/drugs/DB06248
    Investigational

  7. Drug

    2-deoxyglucose

    go.drugbank.com/drugs/DB08831
    Investigational

    Although there are several possible therapeutic indications for 2-deoxyglucose, presently there is no approved indication for 2-deoxyglucose as a therapeutic agent. … 2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel).

  8. Drug

    Ferrous chloride

    go.drugbank.com/drugs/DB13569
    Investigational

    Mixtures: Nutritrace Concentrate for solution for infusion
  9. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

  10. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … [A258493] Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.